Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic NanoparticleLi Zhang1, Nadimpalli RS Varma1, Zhang Z. Gang1, James R. Ewing1, Ali S Arbab2 and Meser M Ali1*
- *Corresponding Author:
- Meser M Ali
Department of Neurology
Henry Ford Hospital
Detroit, MI 48202, USA
Tel: +1- 313-874-4479
E-mail: [email protected]
Received Date: October 18, 2016; Accepted Date: October 25, 2016; Published Date: October 28, 2016
Citation: Zhang L, Varma NRS, Gang Z, Ewing JR, Arbab AS, et al. (2016) Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle. J Nanomed Nanotechnol 7: 404. doi: 10.4172/2157-7439.1000404
Copyright: © 2016 Zhang L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
There is no available targeted therapy or imaging agent for triple negative breast cancer (TNBC). We developed a small-sized dendrimer-based nanoparticle containing a clinical relevant MRI contrast agent, GdDOTA and a NIR fluorescent dye, DL680. Systemic delivery of dual-modal nanoparticles led to accumulation of the agents in a flank mouse model of TNBC that were detected by both optical and MR imaging. In-vivo fluorescence images, as well as ex-vivo fluorescence images of individual organs, demonstrated that nanoparticles accumulated into tumor selectively. A dual modal strategy resulted in a selective delivery of a small-sized (GdDOTA)42-G4-DL680 dendrimeric agent to TNBC tumors, avoiding other major organs.